McNeil v. B-M analgesic ad wars
McNeil seeking to enjoin Bristol-Myer's from continuing its television ads that allegedly claim 400 mg Nuprin (OTC ibuprofen) is more effective than Extra Strength Tylenol. The suit, filed July 11 in U.S. federal court Eastern District of Pennsylvania, argues that the commercial is misleading because the recommended initial dose for OTC ibuprofen is 200 mg. McNeil also noted that it surveyed consumer responses to the ad and found that 74% of the 300 people in the test believed, based on the commercial, that the standard Nuprin dose is two tablets. MeNeil also found that "only 4% of the respondents recalled the 'trailer' -- a non-spoken, visual footnote in the middle of the commercial -- which indicates that the standard Nuprin dose is only one tablet".
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.